Awareness of the features of these tumors, consideration of the possibility of metastasis and appropriate ancillary studies are the keys to the accurate diagnosis of these cases.
DOI: 10.29245/2572-9411/2019/2.1177 Read More Juan Luis Fernández-Martínez*, Oscar Álvarez, Enrique J.
The methodology is particularly well-suited for the case of rare diseases where few genetic samples are at disposal.
We believe that this method for drug optimization is more effective and complementary to the target centric approach that loses efficacy due to a poor understanding of the disease mechanisms to establish an optimum mechanism of action (Mo A) in the designed drugs.
However, when they occur, the metastatic tumors in the testis are usually unilateral and solitary, may have overlap growth patterns and cytological features with primary testicular tumors, including those of rete/epididymis origin, mesothelial origin and Sertoli cell tumor.
It will make the diagnosis very challenging, especially when there is no known history of a primary tumor in other sites.
Related to this is the fact that the disease is most dangerous and deadly when it comes to those individuals with reduced immune system defenses, such as the elderly and very young.
This means that it is a health risk in the public domain that targets the most vulnerable in our society.
De Andrés-Galiana, Javier Fernández-Sánchez de la Viña, Leticia Huergo Group of Inverse Problems, Optimization and Machine Learning. University of Oviedo, Oviedo, 33007, Asturias, Spain.
In this paper we present a robust methodology to deal with phenotype prediction problems associated to drug repositioning in rare diseases, which is based on the robust sampling of altered pathways.